Contrasting Ekso Bionics (NASDAQ:EKSO) and Competitive Technologies (OTCMKTS:CTTC)

Ekso Bionics (NASDAQ:EKSO) and Competitive Technologies (OTCMKTS:CTTC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Ekso Bionics and Competitive Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ekso Bionics	1	0	2	0	2.33
Competitive Technologies	0	0	0	0	0.00

Ekso Bionics currently has a consensus target price of $115.50, suggesting a potential upside of 2,329.02%. Given Ekso Bionics’ stronger consensus rating and higher probable upside, analysts plainly believe Ekso Bionics is more favorable than Competitive Technologies.

Earnings and Valuation

This table compares Ekso Bionics and Competitive Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ekso Bionics	$14.75 million	0.85	-$11.33 million	($5.68)	-0.84
Competitive Technologies	N/A	N/A	N/A	N/A	N/A

Competitive Technologies has lower revenue, but higher earnings than Ekso Bionics.

Profitability

This table compares Ekso Bionics and Competitive Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ekso Bionics	-70.74%	-90.71%	-42.25%
Competitive Technologies	N/A	N/A	N/A

Insider and Institutional Ownership

6.4% of Ekso Bionics shares are held by institutional investors. 6.0% of Ekso Bionics shares are held by insiders. Comparatively, 17.5% of Competitive Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Ekso Bionics beats Competitive Technologies on 5 of the 9 factors compared between the two stocks.

About Ekso Bionics

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.

About Competitive Technologies

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.